J A Talcott
Affiliation: Massachusetts General Hospital
- Time course and predictors of symptoms after primary prostate cancer therapyJames A Talcott
Center for Outcomes Research, MGH Cancer Center, Massachusetts General Hospital, Boston, 02114 2696, USA
J Clin Oncol 21:3979-86. 2003..We characterized the time course of treatment complications while adjusting for potentially confounding pretreatment factors hindering other observational studies...
- Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understandJames A Talcott
Center for Outcomes Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston 02114 2696, USA
J Urol 176:1558-63; discussion 1563-4. 2006..We present an approach that preserves the methodological strengths of validated multi-item measures but provides more accessible information for clinical use...
- Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experienceJames A Talcott
Center for Outcomes Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer 109:1599-606. 2007..To identify patient factors that might account for some of this disparity, men within 6 months of diagnosis were surveyed about health attitudes and behavior...
- Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancerJames A Talcott
Center for Outcomes Research, MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA
JAMA 303:1046-53. 2010..Increased radiation doses improve prostate cancer control but also increase toxicity to adjacent normal tissue. Proton radiation may attenuate adverse effects...
- Out-patient management of febrile neutropeniaJ A Talcott
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Int J Antimicrob Agents 16:169-71. 2000..The data identifying low risk patients, treatment strategies for low risk patients, and additional information required before recommending out-patient management of fever and neutropenia widely are described...
- Quality of life in prostate cancerJames A Talcott
Massachusetts General Hospital, Center for Outcomes Research, Massachusetts General Cancer Centre, 75 Blossom St, Suite 230, Boston, MA 02114 2696, USA
Eur J Cancer 41:922-31. 2005....
- Measuring perceived effects of drinking an extract of basidiomycetes Agaricus blazei Murill: a survey of Japanese consumers with cancerJames A Talcott
Center for Outcomes Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
BMC Complement Altern Med 7:32. 2007..To survey cancer patients who consume an extract of the Basidiomycetes Agaricus blazei Murill mushroom (Sen-Sei-Ro) to measure their self-assessment of its effects and to develop an instrument for use in future randomized trials...
- Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes studyC J Beard
Joint Center for Radiation Therapy, Boston, MA 02115, USA
J Clin Oncol 15:223-9. 1997..To use data from a prospective quality-of-life study to assess differences in disease-specific and general health-related quality-of-life changes after treatment with different external-beam irradiation techniques for prostate cancer...
- Patients' perceptions of quality of life after treatment for early prostate cancerJack A Clark
Department of Health Services, Boston University School of Public Health, Boston, MA 02118, USA
J Clin Oncol 21:3777-84. 2003..Treatment for early prostate cancer produces problematic physical side effects, but prior studies have found little influence on patients' perceived health status. We examined psychosocial outcomes of treatment for early prostate cancer...
- Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort studyJ A Talcott
Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA, USA
J Clin Oncol 16:275-83. 1998..To assess complications of therapy for early (nonmetastatic) prostate cancer...
- United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by regionMary McNaughton Collins
Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Urology 60:628-33. 2002..To examine whether physicians' views on prostate cancer screening and treatment vary by geographic region in the United States...
- Evaluation of a prostate brachytherapy technique designed to reduce short- and long-term urinary dysfunction: 5-year results of a multi-institutional comparative cohort studyJ A Talcott
Center for Outcomes Research, Massachusetts General Hospital Cancer Center, Charlestown, MA Massachusetts General Hospital, Boston, MA Beth Israel Deaconess Medical Center, Boston, MA Boston University School of Public Health, Boston, MA Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA
J Clin Oncol 29:70. 2011....
- Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivorsAnthony L Zietman
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 302, Boston, MA 02114, USA
J Urol 170:1772-6. 2003..Concern exists about the function of the retained bladder after such therapy...
- Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapyHenry K Tsai
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Urol Oncol 23:230-7. 2005..To investigate the impact of 2 months of neoadjuvant and 2 months of concurrent hormonal therapy on the acute gastrointestinal (GI) toxicities associated with 3-dimensional conformal radiation therapy (3D-CRT) for prostate adenocarcinoma...
- Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volumeJoshua H Petit
Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Brachytherapy 6:267-71. 2007..We examined whether prostate volume reduction after a short course of androgen deprivation (AD) lowered the risks of acute and chronic urinary morbidity related to radioactive seed implantation for low-risk prostate cancer...
- Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trialPaul L Nguyen
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 78:1081-5. 2010..2 GyE) or high-dose (79.2 GyE) radiation for prostate cancer...
- New era in prostate-cancer care: what we know and what we don'tJames A Talcott
Center for Outcomes Research, MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Lancet Oncol 4:204-5. 2003
- Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account?Ronald C Chen
Center for Outcomes Research, MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Cancer 112:61-8. 2008..Using patient-reported baseline dysfunction from a prospective cohort study, we determined the proportion of patients receiving relatively contraindicated ('mismatched') treatments...
- Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: a potential early indicator for technology assessment?Pearl H Seo
Massachusetts General Hospital, Boston, MA 02114 2693, USA
Clin Prostate Cancer 3:38-42. 2004..However, these results suggest that measuring early symptoms may indicate whether an altered brachytherapy treatment technique has intended favorable consequences, potentially accelerating technology assessment...
- Long-term quality of life after conventional-dose versus high-dose radiation for prostate cancer: Results from a randomized trial (PROG 95-09)J A Talcott
Massachusetts General Hospital, Boston, MA Loma Linda Medical Center, Loma Linda, CA Boston University School of Public Health, Boston, MA
J Clin Oncol 26:5058. 2008..Therefore, we initiated a cross-sectional patient survey at a minimum of 7 years after treatment to assess their long-term morbidity...
- Sexuality and cancer: conversation comfort zoneR T Penson
The Kenneth B Schwartz Center at Massachusetts General Hospital, Hematology Oncology Department, Boston, Massachusettts 02114 2617, USA
Oncologist 5:336-44. 2000..A sensitive and informed approach to discussing sexuality can provide effective support. The elements of successful dialogue are presented in the PLISSIT model...
- Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treatedJ A Talcott
Massachusetts General Hospital, Harvard Medical School and Boston University School of Public Health, Boston, Massachusetts, USA
J Urol 166:494-9. 2001..The morbidity of patients receiving more recent brachytherapy may be less...
- Assessing suspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodesJ A Talcott
Dana Farber Cancer Institute, Boston, MA 02115, USA
Support Care Cancer 7:31-8. 1999....
- Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancerRonald C Chen
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Cancer 116:1879-86. 2010..The authors undertook the current study to assess the feasibility of incorporating PRO measurement into routine clinical practice and to describe the trajectory of symptom development during treatment...
- Measuring patients' perceptions of the outcomes of treatment for early prostate cancerJack A Clark
Health Services Department, Boston University School of Public Health, and Center for Health Quality, Outcomes, and Economic Research, Edith Nourse Rogers Memorial Veterans Hospital Bedford, Boston, Massachusetts 02118, USA
Med Care 41:923-36. 2003....
- Does prostate brachytherapy that avoids the central zone prevent long-term urinary incontinence? Five-year results of a multi-institutional comparative cohort studyJ A Talcott
Continuum Cancer Care Consortium, New York, NY Massachusetts General Hospital, Boston, MA Beth Israel Deaconess Medical Center, Boston, MA Boston University School of Public Health, Boston, MA Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA
J Clin Oncol 29:4665. 2011..4665 Background: To evaluate a prostate brachytherapy technique (XBT) designed to reduce urinary dysfunction by avoiding central prostate radiation, we prospectively compared outcomes of XBT patients to 2 standard technique (SBT) groups...
- Binary data with two, non-nested sources of clustering: an analysis of physician recommendations for early prostate cancer treatmentR A Betensky
Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
Biostatistics 1:219-30. 2000..We compare this model to a mixed-effects model that implicitly adjusts for both sources of clustering and to models based on the assumption of conditional independence with regard to one source of clustering...
- Long-term QOL outcome after proton beam monotherapy for localized prostate cancerJ Coen
Massachusetts General Hospital, Boston, MA Center for Outcomes Research, Massachusetts General Hospital Cancer Center, Charlestown, MA
J Clin Oncol 29:68. 2011..68 Background: High-dose conformal proton radiation for localized prostate cancer results in favorable clinical outcomes and low toxicity rates. Here, we report long-term quality of life (QOL) outcome for men treated with conformal protons...
- Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual functionRonald C Chen
Center for Outcomes Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA, USA
J Clin Oncol 27:3916-22. 2009..Using levels of treatment-related dysfunction, we address these problems and present the final QOL outcomes of our prospective cohort study of patients with early prostate cancer...
- Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they madeJack A Clark
Center for Health Quality, Outcomes, and Economic Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, USA
J Clin Oncol 24:4457-63. 2006..The many years most men diagnosed with early prostate cancer live after diagnosis allow evolving assessments of their cancer control and their treatment choices, but little is known of these outcomes or the factors that influence them...
- Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States)Jacob H Cohen
Department of Urology, SUNY Downstate Medical School, Brooklyn, NY, USA
Cancer Causes Control 17:803-11. 2006..We investigate differences in disease-free survival among white, black, Hispanic, and Asian patients in a large, population-based database...
- Perceived family history risk and symptomatic diagnosis of prostate cancer: the North Carolina Prostate Cancer Outcomes studyPamela Spain
Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27709 2194, USA
Cancer 113:2180-7. 2008..African American (AA) men remain at significantly greater risk of PrCA diagnosis and mortality than other men. Many factors contribute to the experienced disparities...
- Employment after therapy for localized prostate cancer: widening the perspectiveJames A Talcott
J Natl Cancer Inst 97:948-9. 2005
- Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropeniaLinda S Elting
Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 447, Houston, TX 77030, USA
J Clin Oncol 26:606-11. 2008..We retrospectively compared the outcomes and costs of outpatient and inpatient management of low-risk outpatients who presented to an emergency department with febrile neutropenia (FN)...
- Androgen deprivation as primary treatment for early prostate cancer: should we "just do something"?James A Talcott
J Natl Cancer Inst 94:407-9. 2002
- Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studiesRonald Feld
Department of Hematology and Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada M5G 2M9
Clin Infect Dis 35:1463-8. 2002..Response and safety parameters should be recorded along with readmission rates. If studies use these guidelines, comparisons between studies will be simpler and will lead to further improvements in patient therapy...
- Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancerDavid T Eton
Northwestern University School of Medicine, Evanston, IL 60201, USA
Eval Health Prof 28:142-59. 2005..A fifth item assessing hemorrhoids was poorly correlated with other items. Our analyses supported four related components of BF: diarrhea, rectal urgency, pain, and bother/distress...
- Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessmentCharles Lu
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
J Support Oncol 3:305-12. 2005..These predictors may help clinicians to assess risk in this patient population...
- How could getting screened for prostate cancer hurt you?James A Talcott
Urol Oncol 23:374-5. 2005
- Rebalancing ratios and improving impressions: later thoughts from the prostate cancer prevention trial investigatorsJames A Talcott
J Clin Oncol 23:7388-90. 2005
- Racial differences in mortality among Medicare recipients after treatment for localized prostate cancerPaul A Godley
Division of Hematology Oncology, School of Medicine and the Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 27599 7305, USA
J Natl Cancer Inst 95:1702-10. 2003..We investigated whether racial disparities in outcomes of clinically localized prostate cancer vary by treatment (surgery, radiation therapy, or nonaggressive treatment)...
- Quality of care in prostate cancer: important to start and too important to stop hereJames A Talcott
J Clin Oncol 21:1902-3. 2003
- Prostate cancer quality of life: beyond initial treatment and the patientJames A Talcott
J Clin Oncol 25:4155-6. 2007
- What patients should be told before agreeing to a blood test that could change their livesJames A Talcott
Urology 61:7-9. 2003
- American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerD Andrew Loblaw
Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
J Clin Oncol 22:2927-41. 2004..The focus of this document is on the use, combinations, and timing of various forms of androgen deprivation therapy (ADT) for the palliation of men with androgen-sensitive disease...
- Outcomes Research and Training in OncologyJames Talcott; Fiscal Year: 2005..One approach to these issues is to identify differences in outcomes based on the mode of diagnosis (screening vs. investigation of symptoms). ..